The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population
The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population
复制标题
脑脊液β-淀粉样蛋白42和Tau蛋白在中国人群神经退行性疾病中的辨别能力
DOI：
10.1016/j.jns.2020.116756
复制
发表时间：
2020-05-15
影响因子：
4.4
通讯作者：
Wu, Zhi-Ying
中科院分区：
文献类型：
--
作者：
Ye, Ling-Qi;Li, Xiao-Yan;Wu, Zhi-Ying
简介：近年来，脑脊液中β-淀粉样蛋白42肽和tau蛋白已成为鉴别阿尔茨海默病（AD）和认知正常对照的主要诊断生物标志物。我们知道，一些神经退行性疾病已被报道在神经病理学和临床症状上与AD重叠。为了检查这些生物标志物在AD和其他神经退行性疾病中的区分效用，我们在中国人群中测量了它们。我们用ELISA法测定了240例中国汉族AD患者（n = 82）CSF中A β（42）、t-tau和p-tau（181），并计算了t-tau/A β（42）和ptau（181）/A β（42）的比值，额颞叶痴呆（FTD，n = 20），亨廷顿病（HD，n = 27），多系统萎缩（MSA，n = 24），脊髓小脑共济失调3型（SCA 3，n = 27），肌萎缩侧索硬化症结果：如预期的，除了FTD中升高的CSF t-tau（p >.05）之外，所有生物标志物在AD和非AD组之间显示出高区分能力（p <.05）。与对照组相比，FTD（p < .001）和MSA（p < .05）组中tau相关生物标志物显著升高。令人惊讶的是，与对照组相比，我们发现在SCA 3中CSF A β（42）显著增加（p <0.05），HD和ALS组（p < .001），分别实现了高特异性。据我们所知，这是首次在中国汉族人群中进行的综合性研究，证实了CSF A β的鉴别效用（42）以及AD和其他神经退行性疾病之间的tau生物标志物。
Introduction: In the past few years, the beta-amyloid 42 peptide and tau protein in cerebrospinal fluid (CSF) have become primary diagnostic biomarkers in differentiating Alzheimer's disease (AD) and cognitive normal controls. As we know, several neurodegenerative diseases have been reported to overlap with AD in neuropathology and clinical symptoms. To examine the discriminative utility of these biomarkers in AD and other neurodegenerative diseases, we measured them in a cohort of Chinese population.Methods: We measured CSF A beta(42), t-tau and p-tau(181) by ELISA tests and calculated the ratios of t-tau/A beta(42) and ptau(181)/A beta 42 in 240 Chinese Han patients with AD (n = 82), frontotemporal dementia (FTD, n = 20), Huntington's disease (HD, n = 27), multiple system atrophy (MSA, n = 24), spinocerebellar ataxia type-3 (SCA3, n = 27), amyotrophic lateral sclerosis (ALS, n = 36) and controls (n = 24).Results: As expected, all biomarkers showed high discriminative capacity between AD and non-AD groups (p < .05) except for the elevated CSF t-tau in FTD (p > .05). Comparing with the controls, tau related biomarkers significantly elevated in the FTD (p < .001) and MSA (p < .05) groups. Surprisingly, comparing with controls, we found that CSF A beta(42) increased remarkably in the SCA3 (p < .05), HD and ALS groups (p < .001), achieving a high specificity, respectively.Conclusion: To our best knowledge, this is the first comprehensive study in the Han Chinese population that confirmed the discriminative utility of CSF A beta(42) and tau biomarkers between AD and other neurodegenerative diseases.